- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03402893
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- DermResearch, PLLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
i. Outpatient, subjects of skin of color, age 12 or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study;
A female is considered of childbearing potential unless she is:
- postmenopausal for at least 12 months prior to study drug administration
- without a uterus and/or both ovaries; or
- has been surgically sterile for at least 6 months prior to study drug administration
Reliable methods of contraception are:
- intrauterine device in use ≥ 90 days prior to study drug administration;
- barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
- vasectomized partner
[Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.]
ii. Facial acne vulgaris in patients with skin of color (Fitzpatrick Type V & VI Supplement VI) characterized by the following:
- IGA Score for acne vulgaris 3
- IGA Score for PIH 3
iii. Able to understand and comply with the requirements of the study and sign Informed Consent /HIPAA Authorization forms
Exclusion Criteria:
i. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control
ii. Allergy/sensitivity to any component of the test treatment
iii. IGA score for acne of 2 (mild) or 4 (severe)
iv. IGA score for Post Inflammatory Hyperpigmentation of 2 (mild) or 4 (severe)
v. Subjects who have not complied with the proper wash-out periods for prohibited medications (Supplement I).
vi. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study
vii. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris
viii. Evidence of recent alcohol or drug abuse
ix. History of poor cooperation, non-compliance with medical treatment, or unreliability
x. Exposure to an investigational study drug within 30 days of the Baseline Visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm Onexton gel application
Onexton gel will be supplied to all subjects and applied once daily to the face
|
Onexton gel applied once daily to face
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator Global Assessment Scale for Severity of Facial Acne
Time Frame: Week 4, Week 8, Week 16
|
Percent of subjects achieving clear or almost clear on Investigator's Global Assessment (IGA) scale for facial acne; the IGA scale for acne reflects the Investigator's assessment of the severity of a subject's acne on a scale from 0 to 5 with 0 = Clear Skin, 1 = Almost Clear, 2 = Mild, 3 = Moderate severity, 4 = Severe, 5 = Very Severe Each of these gradations is based upon a lesion count by the Investigator.
|
Week 4, Week 8, Week 16
|
Investigator Global Assessment Scale for Severity of Post Inflammatory Hyperpigmentation
Time Frame: Week 4, Week 8, Week 16
|
Percent of subjects achieving clear or almost clear on Investigator's Global Assessment (IGA) scale for severity of post inflammatory hyperpigmentation; the IGA scale of post-inflammatory hyperpigmentation reflects the Investigator's assessment of the severity of a subject's hyperpigmentation on a scale from 0 to 6 with 0 = None, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = moderately Severe, 5 = Severe, 6 = Very severe Each of these gradations is based upon the investigator's impression
|
Week 4, Week 8, Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Inflammatory Lesions
Time Frame: Week 4, Week 8, Week 16
|
The Investigator will count the number of facial (from hairline to mandibular line) inflammatory acne lesions at each study visit.
Inflammatory lesions include papules, pustules and nodules.
|
Week 4, Week 8, Week 16
|
Percent Change in Non-inflammatory Lesion Count
Time Frame: Week 4, Week 8, Week 16
|
The Investigator will count the number of facial non-inflammatory acne lesions at each study visit.
these include open and closed comedones.
|
Week 4, Week 8, Week 16
|
Percent Change in Total Lesion Count
Time Frame: week 4, Week 8, Week 16
|
The Investigator will count the number of facial inflammatory and non-inflammatory acne lesions at each study visit.
These include papules, pustules, nodules, and open and closed comedones.
|
week 4, Week 8, Week 16
|
Post-Inflammatory Hyperpigmentation (PIH) Distribution
Time Frame: baseline, Week 4, week 8, week 16
|
This measure as assessed by the Investigator seeks to quantify the extent to which post-inflammatory hyperpigmentation is distributed across the face, wherein 0= No PIH, 1=1-10% of the face affected, 2=11-20%, 3=21-30%, 4=31-40%, 5=41-50%, and 6=More than 50% of the face.
Lower numbers reflect less severe disease.
|
baseline, Week 4, week 8, week 16
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONX-1701
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on ONEXTON Topical Gel
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Maruho Co., Ltd.CompletedUsual Type Vulval Intraepithelial Neoplasia (uVIN)Netherlands
-
Maruho Co., Ltd.Completed
-
Maruho Co., Ltd.CompletedAcne VulgarisUnited States
-
Maruho Co., Ltd.Leiden University Medical CenterCompletedCondylomata Acuminata (External)Netherlands
-
Lakewood-Amedex IncPrimeVigilance; Professional Education and Research InstituteTerminated
-
Glia, LLCORA, Inc.CompletedChronic Ocular Graft-versus-host DiseaseUnited States